NO20041792L - Peptider som virker bade som GLP-1-reseptoragonister og glukagonreseptorantagonister og deres farmakologiske fremgangsmater for anvendelse - Google Patents

Peptider som virker bade som GLP-1-reseptoragonister og glukagonreseptorantagonister og deres farmakologiske fremgangsmater for anvendelse

Info

Publication number
NO20041792L
NO20041792L NO20041792A NO20041792A NO20041792L NO 20041792 L NO20041792 L NO 20041792L NO 20041792 A NO20041792 A NO 20041792A NO 20041792 A NO20041792 A NO 20041792A NO 20041792 L NO20041792 L NO 20041792L
Authority
NO
Norway
Prior art keywords
glp
pharmacological methods
receptor antagonists
peptides acting
receptor agonists
Prior art date
Application number
NO20041792A
Other languages
English (en)
Norwegian (no)
Inventor
Clark Pan
James Whelan
Kevin Clairmont
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of NO20041792L publication Critical patent/NO20041792L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20041792A 2001-10-05 2004-05-03 Peptider som virker bade som GLP-1-reseptoragonister og glukagonreseptorantagonister og deres farmakologiske fremgangsmater for anvendelse NO20041792L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32773001P 2001-10-05 2001-10-05
PCT/US2002/031693 WO2003040309A2 (en) 2001-10-05 2002-10-04 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use

Publications (1)

Publication Number Publication Date
NO20041792L true NO20041792L (no) 2004-07-02

Family

ID=23277790

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041792A NO20041792L (no) 2001-10-05 2004-05-03 Peptider som virker bade som GLP-1-reseptoragonister og glukagonreseptorantagonister og deres farmakologiske fremgangsmater for anvendelse

Country Status (28)

Country Link
US (6) US7399745B2 (zh)
EP (1) EP1436330A4 (zh)
JP (1) JP2005508639A (zh)
KR (1) KR20050034580A (zh)
CN (1) CN1326876C (zh)
AR (1) AR036711A1 (zh)
BR (1) BR0213132A (zh)
CA (1) CA2462462A1 (zh)
CO (1) CO5570710A2 (zh)
DO (1) DOP2002000475A (zh)
EC (2) ECSP024346A (zh)
HK (1) HK1073117A1 (zh)
HN (1) HN2002000282A (zh)
HR (1) HRP20040327A2 (zh)
HU (1) HUP0401797A2 (zh)
IL (1) IL160706A0 (zh)
MA (1) MA26228A1 (zh)
MX (1) MXPA04002140A (zh)
MY (1) MY138267A (zh)
NO (1) NO20041792L (zh)
NZ (1) NZ532685A (zh)
PE (1) PE20030850A1 (zh)
PL (1) PL368760A1 (zh)
RU (1) RU2334761C2 (zh)
SG (2) SG158736A1 (zh)
UY (1) UY27469A1 (zh)
WO (1) WO2003040309A2 (zh)
ZA (1) ZA200403322B (zh)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
MXPA05009940A (es) 2003-03-19 2005-12-05 Lilly Co Eli Compuestos de glp-1 de enlace de glicol polietilenico.
WO2004111078A2 (en) * 2003-06-18 2004-12-23 Theratechnologies Inc. Compounds that modulate the glucagon response and uses thereof
RU2006120079A (ru) 2003-12-18 2008-01-27 Ново Нордиск А/С (DK) Производные глюкагоноподобного пептида-1 (glp-1)
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1959986B1 (en) * 2005-11-07 2014-07-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
JO2945B1 (en) 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
CN101578102B (zh) * 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
EP2111414B1 (en) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2008098693A2 (en) * 2007-02-16 2008-08-21 Bayer Healthcare Ag Convergent synthesis of glp-1
MX2010004298A (es) * 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
EP2217701B9 (en) 2007-10-30 2015-02-18 Indiana University Research and Technology Corporation Glucagon antagonists
ES2382579T3 (es) * 2007-12-11 2012-06-11 Cadila Healthcare Limited Peptidomiméticos con actividad antagonista de glucagón y agonista de GLP-1
WO2009099763A1 (en) * 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
AR070844A1 (es) 2008-03-27 2010-05-05 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
PA8830501A1 (es) * 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
EA020326B9 (ru) * 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
MX2010012695A (es) * 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
RU2550696C2 (ru) 2008-12-19 2015-05-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Основанные на амидах пролекарства пептидов глюкагонового надсемейства
RU2539797C2 (ru) 2009-01-22 2015-01-27 Ново Нордиск Хелс Кеа Аг Производное гормона роста человека с повышенной стабильностью к протеолитическому разрушению, способ получения такого производного, его применение, способ лечения и фармацевтическая композиция
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US9695226B2 (en) 2010-01-22 2017-07-04 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
WO2011143209A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY
CN103179979A (zh) 2010-06-24 2013-06-26 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
US9459187B2 (en) * 2011-03-04 2016-10-04 Becton, Dickinson And Company Blood collection device containing lysophospholipase inhibitor
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
LT2723367T (lt) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Bendri gliukagono/glp-1 receptoriaus agonistai
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
AR091477A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
MA43289B1 (fr) 2014-01-20 2019-12-31 Hanmi Pharm Ind Co Ltd Insuline à action prolongée et utilisation associée
WO2015168135A1 (en) * 2014-04-28 2015-11-05 The Trustees Of The University Of Pennsylvania Novel thioamide-modified peptides and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) * 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
WO2016014342A2 (en) 2014-07-21 2016-01-28 Arizona Board Of Regents For The University Of Arizona Ang-(1-7) derviative oligopeptides and methods for using and producing the same
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
WO2018056764A1 (ko) 2016-09-23 2018-03-29 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
TWI798209B (zh) 2017-03-23 2023-04-11 南韓商韓美藥品股份有限公司 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途
EP3891176A1 (en) 2018-12-04 2021-10-13 Københavns Universitet Dual agonist glp-1 and neurotensin fusion peptide
US11934931B2 (en) * 2018-12-17 2024-03-19 Shape Security, Inc. Decision tree training using a database system
EP3986919A1 (en) * 2019-06-18 2022-04-27 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of glucagon
CN115322794A (zh) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2113879T3 (es) * 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
DE69209052T2 (de) * 1991-01-17 1996-11-14 Zymogenetics Inc Verfahren zum nachweis von glucagon-antagonisten
US5846747A (en) * 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5782802A (en) * 1996-03-22 1998-07-21 Vitajet Corporation Multiple use needle-less hypodermic injection device for individual users
US6232310B1 (en) * 1999-03-12 2001-05-15 Novo Nordisk A/S Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists

Also Published As

Publication number Publication date
US20060003417A1 (en) 2006-01-05
MXPA04002140A (es) 2005-03-07
SG149693A1 (en) 2009-02-27
US20060003418A1 (en) 2006-01-05
JP2005508639A (ja) 2005-04-07
UY27469A1 (es) 2003-04-30
WO2003040309A3 (en) 2003-12-18
CN1564828A (zh) 2005-01-12
RU2004114243A (ru) 2005-05-10
AR036711A1 (es) 2004-09-29
ECSP024346A (es) 2003-05-26
WO2003040309A2 (en) 2003-05-15
MY138267A (en) 2009-05-29
PE20030850A1 (es) 2003-10-31
US7488716B2 (en) 2009-02-10
US7488715B2 (en) 2009-02-10
US7494978B2 (en) 2009-02-24
SG158736A1 (en) 2010-02-26
US20060003934A1 (en) 2006-01-05
US20060003419A1 (en) 2006-01-05
ECSP045094A (es) 2004-06-28
EP1436330A2 (en) 2004-07-14
EP1436330A4 (en) 2006-01-18
KR20050034580A (ko) 2005-04-14
US20050288248A1 (en) 2005-12-29
MA26228A1 (fr) 2004-07-01
HN2002000282A (es) 2002-12-12
US7399745B2 (en) 2008-07-15
PL368760A1 (en) 2005-04-04
CO5570710A2 (es) 2005-10-31
HUP0401797A2 (en) 2006-08-28
BR0213132A (pt) 2004-10-19
HRP20040327A2 (en) 2007-11-30
HK1073117A1 (en) 2005-09-23
NZ532685A (en) 2006-02-24
DOP2002000475A (es) 2003-06-30
ZA200403322B (en) 2005-05-03
IL160706A0 (en) 2004-08-31
CN1326876C (zh) 2007-07-18
US7488714B2 (en) 2009-02-10
RU2334761C2 (ru) 2008-09-27
US20050153890A1 (en) 2005-07-14
CA2462462A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
NO20041792L (no) Peptider som virker bade som GLP-1-reseptoragonister og glukagonreseptorantagonister og deres farmakologiske fremgangsmater for anvendelse
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20032277D0 (no) Aminotiazoler og deres anvendelse som adenosinreseptorantagonister
NO20043536L (no) Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
NO20032797L (no) Substituerte pyridoindoler som serotonin agonister og antagonister
AU2003273300A8 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
NO20031952L (no) 3-aroylinderivater og deres anvendelse som CB2 reseptoragonister
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1394150T3 (da) 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
CY2015002I2 (el) Glp-1 αναλογα πρωτεϊνων συντηξης
DK1558615T3 (da) Purin-forbindelser og deres anvendelse som cannabinoid receptor ligander
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
DK2208727T3 (da) Diarylethere som opioidreceptorantagonister
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
DK1501809T3 (da) Trizolderivater som tachykininreceptorantagonister
DK1448535T3 (da) Benzamid og heteroarylamid som P2X7-receptor antagonister
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
IS7324A (is) Samrunnin heterósýklísk sukkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
NO20025640L (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptorantagonister
DK1581518T3 (da) Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
NO995482D0 (no) Ergolinderivater og deres anvendelse som somatostatinreseptorantagonister
NO20043580D0 (no) Quinazolinonderivater og deres bruk som CB agonister
NO20040499L (no) Substituerte pyridin-4-oner og deres andvendelse som gonadotropin-frigjorende hormon reseptor antagonister.
NO20025762D0 (no) Bicykliske cykloheksylaminer og anvendelse derav som NMDA- reseptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application